[Layout: Two columns with a header at the top.]

CHAPTER 6: Evidence-based Practices 311

89 SAMHSA Center for Behavioral Health Statistics and Quality (2023). National Survey on Drug Use and Health. Table 5.9A—Alcohol use disorder in past year: among people aged 12 or older; by age group and demograph­ic characteristics, numbers in thousands, 2021 and 2022. https://www.samhsa.gov/data/sites/default/files/reports/rpt42728/NSDUHDetailedTabs2022/NS­DUHDetailedTabsSect5pe2022.htm#tab5.9a

90 SAMHSA (2021). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration. https://store.samhsa.gov/product/tip-63-medications-opi­oid-use-disorder/pep21-02-01-002

91 Ibid.

92 SAMHSA and the National Institute on Alcohol Abuse and Alcoholism (2012). Medication for the treatment of alcohol use disorder: A brief guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration http://store.sam­hsa.gov/shin/content/SMA15-4907/SMA15-4907.pdf.

93 SAMHSA, Center for Behavioral Health Statistics and Quality (2022.). National Survey on Drug Use and Health. Table 5.22B – Received medication-assisted treatment (MAT) for alcohol use in past year: among people aged 12 and older with past year alcohol use disorder; by demographic char­acteristics, percentages, 2021 and 2022. [cited 2023 Dec 13]. https://samhsa.gov/data/sites/default/files/reports/rpt42728/NSDUHDetailedTabs2022/NSDUH­DetailedTabsSect5pe2022.ht­m?s=5.32&#tab5.22b

94 Center for Substance Abuse Treatment (2009). Incor­porating alcohol pharmacotherapies into medical practice. Treatment Improvement Protocol 49. (HHS Publication No. [SMA] 12-4389.) Rockville, MD: Substance Abuse and Mental Health Services Administration. https://store.samhsa.gov/product/tip-49-incorporating-alco­hol-pharmacotherapies-medical-practice/sma13-4380

95 Avery, J. (2022). Naltrexone and alcohol use. American Journal of Psychiatry, 179, 12. https://doi.org/10.1176/appi.ajp.20220821

96 SAMHSA (2021). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration. https://store.samhsa.gov/product/tip-63-medications-opi­oid-use-disorder/pep21-02-01-002

97 SAMHSA (2024). Certification of Opioid Treatment Pro­grams (OTPs); 42 Code of Federal Regulations (C.F.R.) 8. https://www.samhsa.gov/medications-sub­stance-use-disorders/statutes-regulations-guide­lines/42-cfr-part-8

98 SAMHSA (2021). Medications for opioid use disorder. Treat­ment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration.

99 Kjome, K. L. & Moeller, F. G. (2011). Long-acting in­jectable naltrexone for the management of patients with opioid dependence. Substance Abuse, 5, 1–9. doi: 10.4137/ SART.S5452. Epub 2011 Feb 6. PMID: 22879745; PMCID: PMC3411517. https://www.ncbi.nlm.nih.gov/pmc/arti­cles/PMC3411517/

100 SAMHSA (2021). Medications for opioid use disorder. Treat­ment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration.

101 SAMHSA (2023, May). SAMHSA Advisory: Evidence-based whole-person care for pregnant people with opioid use disor­der. https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf

102 SAMHSA (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Admin­istration. https://store.samhsa.gov/sites/default/files/sma18-5054.pdf

103 American College of Obstetricians and Gynecologists (2021, reaffirmed). Opioid use and opioid use disorder inpregnancy. Committee opinion 711. https://www.acog.org/clinical/clinical-guidance/committee-opinion/arti­cles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy.

104 Center for Substance Abuse Treatment (2005). Medi­cation-assisted treatment for opioid addiction during pregnancy. In: Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Im­provement Protocol (TIP) Series, No. 43. Rockville (MD): Substance Abuse and Mental Health Services Adminis­tration.

105 Centers for Disease Control and Prevention (2022, Nov.). Treatment for opioid use disorder before, during, and after pregnancy. https://www.cdc.gov/pregnancy/opi­oids/treatment.html

106 Hudak, M. L., Tan, R. C., Committee on Drugs, & Com­mittee on Fetus and Newborn. (2012). Neonatal drug withdrawal. Pediatrics, 129, e540–e560. doi:10.1542/ peds.2011-3212. https://pubmed.ncbi.nlm.nih.gov/22291123/

107 Ibid.

108 American College of Obstetricians and Gynecologists (2021, reaffirmed). Opioid use and opioid use disorder inpregnancy. Committee opinion 711. https://www.acog.org/clinical/clinical-guidance/committee-opinion/arti­cles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy